I-Corps: Point-of-Care Microfluidic Device for Rapid Pathogen Detection

I-Corps：用于快速病原体检测的护理点微流体装置

基本信息

批准号：
1953841
负责人：
XiuJun Li
金额：
$ 5万
依托单位：
University of Texas at El Paso
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2022-07-31
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1953841&HistoricalAwards=false
关键词：
Corps Point Care Microfluidic Device

项目摘要

The broader impact/commercial potential of this I-Corps project stems from the critical need for a low-cost point-of-care (POC) microdevice for rapid detection of pathogen infections, such as whooping cough, in low-resource settings. Whooping cough is the only vaccine-preventable infection that remains endemic in the US. Conventional pathogen detection methods either take a long time or require costly and bulky instruments, limiting their applications for low-resource settings. The new microfluidic device can provide low-cost, rapid and accurate detection of whooping cough at the point of care, enabling rapid and accurate POC detection of whooping cough in rural clinical settings and other venues. The microfluidic device may also be used to detect a variety of other pathogens, such as foodborne pathogens. This I-Corps project is primarily intended to commercialize the microdevice for POC detection of pathogens. The core technology is based on integrated DNA isothermal amplification on a low-cost paper/polymer hybrid microfluidic device. The instrument-free detection by the naked eye minimizes instrumentation requirements, while DNA amplification and 6 primers specific to the target ensure high detection sensitivity and high accuracy, respectively. These significant features allow for low-cost, rapid (45 min), and accurate POC detection of pathogens in low-source settings.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力源于对低资产感染的病原体感染（例如在低资产阶级环境中）快速检测病原体感染（例如百日咳）的迫切需求。百日咳是唯一在美国流行的可预防疫苗的感染。传统的病原体检测方法要么需要很长时间，要么需要昂贵且笨重的仪器，从而限制了其用于低资源设置的应用。新的微流体设备可以在护理点上提供低成本，快速准确的检测百日咳，从而在农村临床环境和其他场所中快速准确地检测百日咳咳嗽。微流体装置也可用于检测各种其他病原体，例如食源性病原体。该I-Corps项目主要旨在将Microdevice商业化以用于POC检测病原体。核心技术基于低成本纸/聚合物混合微流体设备上的集成DNA等温扩增。通过肉眼的无仪器检测可最大程度地减少仪器的要求，而DNA扩增和6个针对目标的引物分别确保了高检测灵敏度和高精度。这些重要特征允许低成本，快速（45分钟）和在低源环境中对病原体的准确检测。该奖项反映了NSF的法定任务，并且使用基金会的知识分子优点和更广泛的影响审查标准，被视为值得通过评估的支持。